CorporatePresentationSeptember2020

NASDAQ:NMRD

Forward-Looking Statements

•  Thispresentationincludesforward-lookingstatementsthataresubjecttomanyrisksanduncertainties.Theseforward-lookingstatements,suchasstatementsaboutNemaura’sshort-termandlong-termgrowthstrategies,cansometimesbeidentifiedbyuseoftermssuchas“intend,”“expect,”“plan,”“estimate,”“future,”“strive,”andsimilarwords.Thesestatementsinvolvemanyrisksanduncertaintiesthatmaycauseactualresultstodifferfromwhatmaybeexpressedorimpliedinthesestatements.

•  TheserisksarediscussedinNemaura’sfilingswiththeSecuritiesandExchangeCommission(the“Commission”),includingtherisksidentifiedunderthesectioncaptioned“RiskFactors”inNemaura’sAnnualReportonForm10-KfiledwiththeCommissioninJune2019asthesamemaybeupdatedfromtimetotime.

•  Nemauradisclaimsanyobligationtoupdateinformationcontainedintheseforward-lookingstatementswhetherasaresultofnewinformation,futureevents,orotherwise.

2

OurMission•  Totodisruptthe$80B+Diabetic1market&thepre-diabetic

marketsbymakingitmucheasierfordiabeticsandpre-diabeticstomakelifestylechangesneededtomanage,reverseorpreventdiabetes.

•  WeexpecttoachievethisbycombiningdigitalcoachingandsupportservicesprovidedbyBEAT®diabeteswithcontinuousglucosemeasurements(CGM)&dailyglucosetrenddataprovidedbySugarBEAT®,aCEMarkapprovedNon-invasiveCGM.

•  Within5yearsNemauraaimstoleadinthewearablesmarketandself-managementofmedicalconditionswithourpipelineproductsofsensorsanddigitalhealthcareplatformsusingAI.

•  Employers,healthcareprovidersandinsurersarealready

payingsubstantialfeestosupportpatientsforthelongterm,usingappsandcoaching,soSugarBEAT®CGMcombinedwithBEAT®diabetesdigitalcoachingarepoisedtodisruptthisspace.

NASDAQ:NMRD31.

https://www.marketwatch.com/press-release/856-billion-diabetes-care-devices-drugs-market-size-share-global-opportunity-analysis-and-industry-forecast-2017-2022-2019-01-30

InvestmentHighlights

ü  Non-invasiveCGM(continuousglucosemonitor)SugarBEAT®,combinedwithdigitalcoachingandsupportservicesprovidedbyBEAT®diabetestargetingasignificantGlobalopportunity:

•  Theglobaltype2diabetesmarketissettoreach$58.7billionby20251

•  GlobalDigitalDiabetesMarketOutlookto2026:$16+Billion2

•  $50B+pre-diabeticmarket3

•  Wearablehealth-techsectorexpectedtocomprise$60B+weightloss&wellnessmarkets4

ü  USFDAapprovalandlaunchanticipatedbyendof2021.

ü  CEMarkApproved;RevenuesfromsalesinUK&IrelandandGermanyexpectedinQ42020.

ü  RevenuesfromlaunchofproBEATexpectedtocommenceinUSAfromQ42020–aspartofType2managementandDiabetespreventionprogramwithgrossmarginsofupto75%

NASDAQ:NMRD

1.  https://drug-dev.com/global-type-2-diabetes-market-set-to-almost-double-to-58-7-billion/

2.  https://www.prnewswire.com/news-releases/global-digital-diabetes-market-outlook-to-2026-a-16-billion-industry-opportunity-300980794.html

3.Assuming50%usageascomparedtotypeIInoninsulinmarket-https://www.absolutemarketsinsights.com/reports/Global-Noninsulin-Therapies-for-Diabetes-Market-2019-2027-259

4.JuniperResearchDigitalHealthReportJan142019https://www.juniperresearch.com/press/press-releases/healthcare-spend-in-wearables-reach-60-bn-2023

BEAT®diabetesprovidesdigitalcoachingandsupportservices

SugarBEAT®providescontinuousglucosemeasurements(CGM)&dailyglucosetrenddata

4

SugarBEAT®•  Webelievewearepoisedtodisruptthemulti-billiondollarglucosetrending

anddiabetesmanagementspace•  SugarBEAT®isanon-invasiveCGM(ContinuousGlucoseMonitor)wherethe

sensorsitsontopoftheskin.Doesnotrequireneedlesanddoesnotpuncturetheskintoinsertasensor

•  SugarBEAT®isaflexibleCGMwhichcanbewornforasingledayatatime,withnocommitmenttowearthedevicecontinuouslyfor10-14daysasisthecasewithotherCGM,makingitunlikelythatthedailycost-of-usecanbematchedbyourcompetitors

•  CEapprovedClassIIBMedicalDevice•  USFDAPMAapprovalandlaunchanticipatedbyendof2021•  EUcommerciallaunchfirst,withU.S.andotherstofollow.•  EmpoweringGlucoseTrenddataoverthecourseoftheday,with

measurementsrecordedevery5minutes•  Replacingpointintimefinger-stickmeasurementswhichprovideverylittleand

oftenmisleadinginformationasthepreviousandsubsequentreadingsarenotknown

NASDAQ:NMRD 5

HowSugarBEAT®Works•  Asmalltransmitterdeviceandanadhesivepatchwithasensorsitsontopoftheskin,typicallyontheupperarm.•  Thesystempainlesslydrawssmallamountsofglucosemoleculesoutoftheinterstitialfluidjustbelowthetoplayerofskinintoachamberwithinthepatch.Doesnotrequireneedlesandsensordoesnotpuncturetheskin.•  Therechargeabletransmittermeasuresglucoselevelswithinthechamber,andtransmitsthisdataeveryfiveminutesviaBluetoothtoamobilephoneapp.•  Usingaproprietaryalgorithm,theappthendisplaysthisdataasglucosevalueonsmartphone/deviceingraphicalformataswellasnumericvalues.

NASDAQ:NMRD

6

BEAT®DiabetesProgram

NASDAQ:NMRD

Cardiovascular Risk Monitoring

Blood Glucose Monitoring

Continuous Glucose

Monitoring

Heart Metrics

Diabetes Lifestyle App

Digitally Connected

Online Community

Blood Testing Personalised

Lifestyle Coaching 7

SugarBEAT®CompetitiveAdvantages

Safe –MARD (Mean Absolute Relative Difference) 12.4% with one calibration per day (Internal Clinical Evaluation Report) Insulin-dosing decisions with adjunctive finger stick Predictive alerts and real-time CGM capabilities

Hypo-allergenic - Daily new patch location No skin penetration by sensor Uses Milder skin adhesives

Environmentally friendly – Rechargeable transmitter – 2 year life

Affordable – lower monthly costs

Flexible-use - Freedom to decide WHEN & HOW LONG to wear during the course of the day

Non-Invasive – (Needle Free) Sensor patch sits on top of the skin

NASDAQ:NMRD

TAM:TotalAddressableMarket

8

OpportunitiesforapplicationofbigdatainthehealthindustryTheValueofMedicalDataRealtimeMobiletechnologyhasbeenoneofthelargestcontributorstobigdataforthepastseveralyears.Proliferationofmobilephones,theimplementationofapp-enabledsmartphones,andnowthegrowthofthewearabledevicemarketareallcreatingmassivenewdataflowsthatcanbeputtouseforhealthandotherpurposes.

Wearablemedicaldevicesarenotnew,buttheyhavelongbeenexpensiveandnotalwaysviableforeverypatientorsubjectofamedicalstudytowear.That’swhythegrowthofthewearablepersonalelectronicdevicemarket–andthelowerpricesthatcomewithahighervolumeofdevicesbeingsold–issuchapotentiallygame-changingmomentforbigdatainthehealthindustry

ExtractingpersonaldatafromwearableMedicaldevices:

•  PredictiveanalyticsisbasedonlogicthatisdrawnfromthewearableMedicaldevicesusesanalgorithmtoseekpatternsandstructureindataandclusterthemintogroupsorinsights.

•  Improvingefficienciesperpatient’smanagementofhealthcare

•  Accuracyofdiagnosisandtreatmentinpersonalmedicine

•  Increasedinsightstoenhancelifestyle,diabetes,drugmanagementandcohorttreatment

InitialdevelopmentofArtificialIntelligenceandintermittenttestingusingSugarBEAT®hasthepotentialtodisruptdiabetesmanagementfromthefollowingperspectives:

•  EmpoweringuserswithinterpretationsofSugarBEAT®data.EmpoweringIndustrysuchasBigPharmatoenhancedrugtreatmentregimensanddeveloppersonalizedtherapy.

•  Seekingtocapitalizeonthisapproachtomakinglargedatasetsmoreaccessible,theU.S.NationalInstitutesofHealth—thepreeminentU.S.governmentmedicalresearchorganization,whichoverseesanannual$41.7billionbudget1—isnowworkingwithIBMtoconnectaverywidevarietyofclinicalandresearchdatasetstotheIBMWatsonsystem.

NASDAQ:NMRD

SugarBEAT®

1.https://www.nih.gov/about-nih/what-we-do/budget

9

NemauravsLivongo®The technical difference!

Starts with a supporting approved medical device.

TheTrendsInMobileHealthcare•  Whatweareseeingisashifttowardsdigitalmedicalcare.Therecordsaremoreoftenkeptelectronically,therearemoreopportunitiesforremotepatientmonitoring,andmoretoolsforindividualhealthmonitoringareemerging.Digitalhealthdealsarebooming:thevalueofinvestmentsreached$7.5billionin20192.

•  Nemauraisthelatestbreakthroughinmobile/wearablehealthcaretechnologyregardingfunctionality,technology,interconnectivityandallsupportedwithrealmedicaldiagnosticsfromtheirCEapprovedmedicaldevice.

Livongo®Limitations:(NASDAQ:LVGO)•  Livongo®forDiabetes:includesacellular-connectedinteractive

glucometer,unlimitedbloodglucoseteststrips,real-timecoaching,and24-hourmonitoring

•  LivongoforPre-DiabetesandWeightManagement:offersacellular-connectedweightscale,healtheducationalcontent,personalizedcoachingservice,andgroupclasses

NemauraAdvantages:•  SugarBEAT®CGMprovidesverypowerfuldatathatwillallowlong

termtherapyandlifestyleadjustmentsthatfingerpricktestingcannotachieve

•  Clinicallyproven,evidencebasedhealtheducationondiabetesthathasbeendemonstratedtoleadtobehavioralchangesindiabetics.On-demandcoachingserviceforpersonalfitness,motivation,anddietaryadvice,(throughin-licensingandcollaboration)

NASDAQ:NMRD

1

1.Livongo®isaregisteredtrademarkofLivongoHealth,Inc.2.https://www.digitalhealth.net/2020/01/ces-2020-digital-health-investment-2019/ 10

CommercialStrategy•  Priority1:Subscriptionbasedservice•  Amonthlysubscriptionplannedtogoonlinebyend2020

toreceiveasetnumberofsensorseachmonth,andtheappwhichwillallowtheusertosharetheirdatawithfamilyandcaregivers,andbeabletomonitortheirglucoseprofilerelativetolifestyleinterventionsandhabits.

•  Priority2:DigitalCoaching•  Subscriptionbaseddigitalcoachingsupportingdiabetes/

health/nutrition/exercise/behavioralchangesandmodificationetc.

•  Priority3:AIPlatform•  CreationofAIplatformtoenhanceuserexperience.This

willbedevelopedaswegatherdatafromusers.

•  Priority4:One-to-onedigitalcoaching•  Subscriptionbasedhighvalue,lowvolumeservice,with

coachesrecruitedinalllocalterritories.

NASDAQ:NMRD11

Nemauramedicallaunchstrategy•  Europediabetesdevicesmarketsizewasvaluedat

USD6.4billionin20181•  Nemauratargetmarket:UK,Germany,USA

•  Nemaura'sproductofferingisbeingledbytheirVicePresidentofStrategyandStrategicAlliances,DrFredShaebsdau.

•  FromSeptember2016untilJanuary2019,hewastheGeneralManagerofDexcomGermany,akeyglobalplayerintheCGMmarket,whichduringhisleadershipbecamethefastestgrowingorganizationinDexcom’shistoryachievingtripledigitrevenue,andsubstantialgrowthofusers.

•  Therearecurrentlyaround3.5mdiabetics2and7mpre-diabeticsintheUK3.Thereareover2memployeesinthelargest10UKcompaniesalone4.IntheUK,Nemauraforecasthavingthepotentialofachievingover200,000UKsubscribers.

NASDAQ:NMRD

1.  https://www.grandviewresearch.com/industry-analysis/europe-diabetes-devices-market2.  https://www.diabetes.co.uk/diabetes-prevalence.html3.  https://www.diabetes.co.uk/pre-diabetes.html4.  https://www.economicshelp.org/finance/top-10-companies/

12

NemaurabelievesthenumberofpeoplethatcouldbenefitfromSugarBEAT®issignificantbuteveninascenariowherethiswasonlyrolledoutacrossstaffconsideredtobehighvalueassetstothe100biggestcompaniesintheUK,weforecastthishavingthepotentialofachievingover200,000subscribersintheUK.

NHS(UK)DiabetesPreventionProgram(DPP)DigitalStream

•  DPPtosupport200,000peopleperyeartotransformtheirlifestyles

•  Fivedigitalbehaviorchangeproviders

•  Basedoncontinuousengagementwithpatientstomakenewhabitsandbehaviors

•  Helppatientstoimprovetheirconditionsbypersonalizedhealthlifestyleplansandcoaching

NHS(UK)Type2behaviorchangeatscale•  PartnershipwithNHSEnglandofferingfreedigitalsupportforpeoplediagnosedwithType2diabetes

•  Onlineplatformwilldeliverthisbehaviorchangeservicenationally

•  Evidencebasededucationwithinnovativetechnologytoprovidepersonalizationatscale

SugarBEAT®GlobalMarketopportunityconsistsofthreetargetmarkets:•  Theglobaltype2diabetesmarketissettoreach$58.7billionby20251•  GlobalDigitalDiabetesMarketOutlookto2026:$16+Billion2•  Pre-diabetics—approximately3xdiabeticpopulation

•  $60B+TAMWearableHealth-Techmarket:lowcarb/weightloss/fitness

U.S.CGMMarketOverview2

•  U.S.hasthelargestnumberofCGMusersglobally(630kin2018)Only2.6%of25MUSdiagnoseddiabeticsusedCGMin2018•  U.S.annualCGMusageincreasedby117%in201830%ofU.S.TypeIdiabeticsuseCGM•  3%ofU.S.Type2insulinusersuseCGM

CGMusageamongstnon-insulindiabeticsnegligible•  U.S.has88Mpre-diabetics3

Continuousglucosemonitoring(CGM):TAM

Understandingthe

opportunity1.  https://drug-dev.com/global-type-2-diabetes-market-set-to-almost-double-to-58-7-billion/

2.  https://www.prnewswire.com/news-releases/global-digital-diabetes-market-outlook-to-2026-a-16-billion-industry-opportunity-300980794.html

3.https://www.cdc.gov/diabetes/basics/prediabetes.html NASDAQ:NMRD

13

SugarBEAT®KeyMilestones

1Q2016:SugarBEAT®receivedCEMarkinEuropeonPredecessorProduct(wristwatch)

4Q2017:Successful525patienttrialcompletedinEuropeforSugarBEAT®

1Q2018:NMRDListsonNasdaq

2Q2018:SugarBEAT®beganFDAclinicalprogram

3Q2018:PublishedinterimFDAclinicaldata

2Q2019:CEapprovalOfminiaturisedSugarBEAT®CGM

Endof2020:RevenuesexpectedfromEurope:UKandIrelandfirstfollowedbyGermany,andproBEATinUSA

End2021:TargetFDAapprovalforSugarBEAT®

4Q2018:CompletedtrialsforFDAsubmission

End2021:Launchofsecondlineofproducts&USlaunchofSugarBEAT®

NASDAQ:NMRD14

2Q2020:FDAPMAsubmitted

Current Product Pipeline

NASDAQ:NMRD

Product KeyFeatures Market

SugarBEAT®GenII •  Includepediatriccover•  Improvedaccuracy(MARD)•  Longerpatchweartime•  IncludeGestationaluse

•  TypeIIDiabetics•  Pre-Diabetics•  WearableHealth-Tech•  Pregnancy

ContinuousLactateMonitoring

•  Non-invasiveskinpatchforcontinuouslactatemonitoring

•  Determinesappropriatetrainingintensitylevelsandmonitorsprogression

•  Athletes•  Fitness•  WearableHealth-Tech

marketexpectedtobeworth$60B+by20231

1JuniperResearchDigitalHealthReportJan14201915

FuturePotentialProductPipelineProduct Uses Diagnostics

LactateMonitoring Lactatemonitoringinintensivecare AnaerobicMetabolism

AlcoholMonitoring Supportpersonalhealthgoals,andprovidewarningspriortodriving,andprovidephysicianswithindividualdrinkinghabits

Preventionofprogressiontoalcoholrelateddiseases.

NASDAQ:NMRD16

TheManagementTeam

Dr.FazChowdhuryChiefExecutiveOfficer

Dr.ChowdhuryhasservedasCEOandchairoftheboardofNemauraMedicalsinceformationinDecember2013.Heissoleinventoronmorethan100grantedandpendingpatentsacrossover20technologyplatformswithinthemedicaldeviceandpharmaceuticalsectors.Hehas20yearsexperienceandtrackrecordtakingproductsfromconcepttoapproval,andhasbeenpivotalinthecompany’stechnicalandstrategicdevelopment.HehasauthoredTextbookChaptersonNano-biosciencesforWileyandElsevier,andservesontheBoardofMedilinkEastMidlands,UK.Dr.ChowdhuryholdsaMastersinMicrosystemsandNanotechnologyfromCranfieldUniversity,UK,andDoctoratefromtheUniversityofOxfordonnano-medicineanddrugdelivery.

ChrisAveryVicePresident-GlobalBusinessOperations

Mr.Averyhas35years’experienceindiabetes,gainingvastexperienceinglucosemonitoringandinsulindeliverymarkets.Heco-foundedaUKdiabetesdistributorshipin2000andservedasUKManagingDirectorandEuropeanDirectorlateracquiredbyNipro.Todatehehassuccessfullylaunchedover20glucosesystemseitherdirectorwithdistributorsandnegotiatedpartnershipsanddistributiondealswithpharmaceutical&medtechcompaniesacrossEuropeandotherinternationalmarkets.In2016hejoinedNemauraMedical’sEuropeanJVpartner,DallasBurstonEthitronixasSVPGlobalBusinessDevelopment,andworkedcloselywithDr.ChowduryuntiljoiningNemauraMedicalinJune2019.

Dr.FredSchaebsdauVPStrategyandStrategicAlliances

Dr.Schaebsdauhasover15yearsofexecutivelevelexperienceintheCGM,BloodGlucoseMonitoring(BGM)andinsulindeliveryindustries,whichstartedin2004duringhistenurewithAbboqDiabetesCare,wherehewasamemberoftheM&Aandpost-mergerintegrationteamsresponsiblefortheacquisitionofTheraSenseanditsFreeStyleNavigatorCGM.FromSeptember2016untilJanuary2019,hewastheGeneralManagerofDexcomGermany,whichduringhisleadershipbecamethefastestgrowingorganizationinDexcom’shistoryachievingtripledigitrevenueandnewpatientgrowtheveryyear.

NASDAQ:NMRD17

AdditionalseniorhighprofilehiresinprogressinUSAandEU.

Intellectual Property BuildinganextensiveintellectualpropertyportfoliotopositiontheCompanytobecomealeaderinthenon-invasiveCGMspace

TheCompanyhasseveralpatentfamiliesspanningthefollowing:

1.  Sensorrelated

2.  AlgorithmandmethodsofusingtheCGMdata

3.  Devices&methodstoenhanceglucosesensing

4.  Methodstoenhanceglucosesensing

5.  Devicesandmethodstoextractglucose

TheCompanyanticipatesfilingmultipleadditionalpatentsoverthecourseofthenext18monthsbasedonongoingfindingsandimprovements.

NASDAQ:NMRD18

SummaryNemauraMedicalaimstodominatetheglobaldiabetesmarketsforputtingType2diabetesintoremission,usingtheSugarBEAT®deviceanddigitalhealthcareplatform.

•  Within5yearsthecompanyaimstoleadinthewearablesmarketandself-managementofmedicalconditionswithitspipelineproductsofsensorsanddigitalhealthcareplatformusingAI.

•  Thecompanyhasthepotentialtodisruptthemulti-BilliondollarglucosetrendinganddiabetesmanagementspacetargetingasignificantGlobalopportunity:

•  Revenuesexpectedfromend2020fromUSA,UKandGermany,withgrossmarginsofupto75%.

DigitalhealthsectorcomprisingthetypeIIdiabeticmarket&pre-diabeticmarket

•  AimingtobuildontheLivongomodel,butusingthecompany’sproprietaryuniquedeviceplatform,henceamoresubstantialproposition

•  Grossmarginsofupto75%CurrentBalancesheet(atendAugust2020)

•  Approx.$18mcash•  Cashburnrateapprox.$1mperquarter(asofAugust2020)•  Capitalizedtofundalloperationsforupto2years,andseethroughto

revenuesfromUSAandGermanyandUKfromend2020onwards.

NASDAQ:NMRD19